After winding down its oncology program to pivot to multiple sclerosis (MS), TG Therapeutics has suffered a fresh setback as its lead candidate faces an additional three-month wait for an FDA decision.
[Fierce Biotech]
Home Newsletters Immune Regulation News After Oncology Wind-Down, TG’s Pivot to MS Faces Setback as FDA Pushes...
